Rating Scale News Today

in southern virginia. i am jon scott and this is the box report. lets get right to lucas tomlinson at the white house with the latest. prince jon, we are learning that took off from elizabethan tennessee that north tennessee not far from the border of rigid and affluent all the way as far northeast as long island before mysteriously turned around coming back and crossing over restricted airspace above the nations capitol for crash landing i to have our drive from here. for the d.c. nat...

Topline data were announced from the phase 2/3 HEALEY ALS Platform trial evaluating SLS-005 for amyotrophic lateral sclerosis (ALS).

Amylyx Pharmaceuticals, Inc. today announced that several abstracts detailing data on AMX0035 and the Company’s investigational antisense oligonucleotide, AMX0114, for the potential treatment of...

02.11.2023 - Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the ...

/PRNewswire/ - Creyos Health today announced the expansion of its cognitive healthcare platform to include an all-new protocol for more accurate and objective...

Is psilocybin a viable treatment for MDD? Researchers performed a phase 2, double blind trial of single-dose psilocybin in patients with treatment resistant depression.

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...

FDA advisory committee meeting to discuss NurOwn® for Amyotrophic Lateral Sclerosis scheduled for September 27, 2023 BrainStorms Biologics License Application for NurOwn has a Prescription... -Today at 07:06 am- MarketScreener

In the largest study of its kind to date, researchers found promising results for subcutaneous ketamine for treatment resistant depression.